CSI Market
Sign In | Register

Kyntra Bio Inc (KYNB) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access KYNB quarterly Cash Flow →
This cash flow overview for Kyntra Bio Inc spans from Dec 31 2021 to Dec 31 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income183.45
Depreciation & amortization0.71
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets to be Disposed of2.06
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories5.36
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Business-52.55
Share-based Compensation6.58
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt6.58
Investment Income Amortization Of Premium-
Income Tax Expense Benefit Unrealized Holding Gain Loss On Available For Sale Securities-
Increase Decrease In Contract With Customer Liability-136.43
Finance Lease Right Of Use Asset Amortization0.04
Unrealized Loss Gain On Equity Investments-
Investment Gain Loss In Unconsolidated Variable Interest Entity-2.49
Non Cash Interest Expense Related To Sale Of Future Revenues-
Non Cash Change In Accrued Interest Expense And Payments Related To Sale Of Future Revenues-
Impairment Of Investments-
Increase Decrease In Operating Lease Right Of Use Assets0.81
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-2.54
Increase (Decrease) in Accounts Payable-27.65
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-53.50
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets54.10
Other Working Capital-0.41
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities11.10
Discontinued operations0.00
Net Cash flow from Operating Activities-4.77
Investing Activities
Capital Expenditures-0.04
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Available-for-sale Securities, Debt-61.16
Real Estate Investments0.00
Payments To Acquire Available For Sale Securities And Term Deposit-
Payment Made For Investment In Unconsolidated Variable Interest Entity-
Proceeds From Sales Of Available For Sale Securities-
Payment To Divestiture Of Businesses-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested96.62
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities35.42
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.05
Long-term debt - borrowings0.00
Long-term debt - repayments-75.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock-5.35
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-5.62
Proceeds From Lease Financing Liability-
Proceeds From Initial Public Offering Net Of Underwriting Discounts And Commission Costs-
Proceeds From Follow On Offering Net Of Underwriting Discounts And Commission Costs-
Finance Lease Principal Payments-
Repayments Of Finance Lease Liabilities-0.01
Proceeds From Sale Of Future Revenues Net Of Issuance Costs-
Payments For Transaction Costs Related To Sale Of Future Revenues-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-86.03
Effect of exchange rate on cash flow1.08
Discontinued operations0.00
Free Cash Flow-4.81
Total Cash Flow-6.43
4 historic quarters locked

Sign in to unlock the full Kyntra Bio Inc cash flow history.

Sign In Create Free Account

About Kyntra Bio Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-108346

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License